Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07495956
PHASE1/PHASE2

cfMSC Therapy for Diabetes

Sponsor: Shenzhen Geno-Immune Medical Institute

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the feasibility, safety and clinical efficacy of the novel clonal fetal mesenchymal stem cell (cfMSC) therapy in patients with type II diabetes mellitus.

Official title: Clonal Fetal Mesenchymal Stem Cell (cfMSC) Therapy for Type II Diabetes Mellitus

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2026-03-16

Completion Date

2030-04-30

Last Updated

2026-03-27

Healthy Volunteers

No

Interventions

BIOLOGICAL

cfMSC therapy for diabetes

Clonal fetal mesenchymal stem cells (cfMSCs) therapy for type II diabetes mellitus

Locations (1)

Shenzhen Geno-immune Medical Institute

Shenzhen, Guangdong, China